Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2011 ) > List of Articles

ORIGINAL ARTICLE

Differentially Altered Plasma Proteins in Patients diagnosed with Alcoholic and Nonalcoholic Fatty Liver Disease

Kamlesh K Bhopale, Dhananjaya Nauduri, Kizhake V Soman, Gagan K Sood, Anthony Okorodudu, GAS Ansari, Bhupendra S Kaphalia

Citation Information : K Bhopale K, Nauduri D, V Soman K, K Sood G, Okorodudu A, Ansari G, S Kaphalia B. Differentially Altered Plasma Proteins in Patients diagnosed with Alcoholic and Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2011; 1 (2):89-99.

DOI: 10.5005/jp-journals-10018-1019

License: CC BY-NC 4.0

Published Online: 01-07-2011


Abstract

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are major health problems. Although both diseases follow a similar course of disease progression from an early reversible fatty liver stage to severe necroinflammation with or without fibrosis and cirrhosis, the mechanisms of ALD and NAFLD are not well understood. This preliminary study was conducted to determine blood alcohol concentration (BAC) and altered proteins and fatty acid ethyl esters (FAEEs, nonoxidative metabolites of ethanol) in the plasma of patients diagnosed with ALD or NAFLD. Differentially altered proteins were identified by two-dimensional gel electrophoresis and mass spectrometry, FAEEs by gas chromatography and BAC by an enzymatic method. Precursors of complement C3, complement C6 and serum amyloid A-4 protein, and Ig gamma-3 chain C region were significantly decreased in ALD vs controls (group 1). Haptoglobin precursor was the only altered protein (increased) in NAFLD vs controls (group 2). However, significantly increased levels of precursors of complements C3, C4-B and C6 and decreased levels of immunoglobulin J chain and Leucine-rich alpha-2 glycoprotein precursor were observed in NAFLD vs ALD (group 3). These results indicate potential of precursors of complements C3 and C6 and haptoglobin for the differential diagnosis of ALD and NAFLD. Although high BAC and plasma FAEEs levels in the ALD group appear to be associated with chronic alcohol abuse, biological significance of endogenous biosynthesis of FAEEs yet to be established. Therefore, a detailed proteomic and lipidomic study need to be conducted in larger cohorts to understand the etiopathogenesis of ALD and NAFLD.


PDF Share
  1. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology 2003;124:248-50
  2. New concepts in the pathogenesis of alcoholic liver disease. Expert Rev Gastroenterol Hepatol 2008;2:749-59
  3. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010;51:111-20
  4. Office of the Secretary. National Institute on Alcohol Abuse and Alcoholism (US). 10th special report to the US Congress on alcohol and health: Highlights from current research from the Secretary of Health and Human Services. [Rockville, Md], US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism 2000
  5. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984;2:241-44
  6. Obesity, hyperlipidemia and metabolic syndrome. Liver Transpl 2009;15(S2):S83-89
  7. Fatty acid ethyl esters: Markers of alcohol abuse and alcoholism. Alcohol 2004;34: 151-58
  8. Metabolic basis of ethanolinduced hepatic and pancreatic injury in hepatic alcohol dehydrogenase deficient deer mice. Alcohol 2006;39:179-88
  9. Pancreatic injury in hepatic alcohol dehydrogenase-deficient deer mice after subchronic exposure to ethanol. Toxicol Appl Pharmacol 2010;246:154-62
  10. Nonalcoholic steatohepatitis, animal models, and biomarkers: What is new? Methods Mol Biol 2010;593:109-36
  11. 1H and 31P NMR lipidome of ethanol-induced fatty liver. Alcoholism: Clinical and Experimental Research 2011;34:1937-47
  12. Quantitative 2D gel electrophoresis-based expression proteomics of albumin and IgG immunodepleted plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008;865:147-52
  13. Functional analysis of the nuclear proteome of human A549 alveolar epithelial cells by HPLC-high resolution 2D gel electrophoresis. Proteomics 2006;6:2656-72
  14. Role of complement in ethanol-induced liver injury. Adv Exp Med Biol 2008;632:175-86
  15. The complement system in liver diseases. Cell Mol Immunol 2006;3:333-40
  16. Lack of plasma complement activation in severe acute alcoholic hepatitis. Alcohol Clin Exp Res 1995;19:1537-40
  17. Complements system in samter’s immunologic diseases. In: Austen KF, Frank K, Atkinson JP, Cantor H (Eds). Complement system, Philadelphia, Lippincott Williams and Wilkins 2001;281-99
  18. Differential contributions of C3, C5, and decay-accelerating factor to ethanolinduced fatty liver in mice. Gastroenterology 2007;132: 1117-26
  19. Association of alcohol consumption and exaggerated immunopathologic effects in the liver induced by infectious organism. Front Biosci 2002;7:d1487-93
  20. Innate immune response and hepatic inflammation. Semin Liver Dis 2007;27:339-50
  21. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J 2005;2:89
  22. Alcohol abuse, immunosuppression, and pulmonary infection. Curr Drug Abuse Rev 2008;1:56-67
  23. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997;40:544-49
  24. Activation of complement components and reduced regulator expression in Differentially Altered Plasma Proteins in Patients diagnosed with Alcoholic and Nonalcoholic Fatty Liver Disease Euroasian Journal of Hepato-Gastroenterology, July-December 2011;1(2):89-99 99 EJOHG alcohol-induced liver injury in the rat. Clin Immunol 2002;105: 57-63
  25. Haptoglobin: Function and polymorphism. Clin Lab 2000;46:547-52
  26. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 2004;91:129-40
  27. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803-08
  28. Down-regulated expression of complement factor I: A potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin Chim Acta 2007;377:119-26
  29. Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury. Clin Chem 1996;42:24-27
  30. Purification and characterization of rat liver microsomal fatty acid ethyl and 2-chloroethyl ester synthase and their relationship with carboxylesterase (pI 6.1). Chem Res Toxicol 1997;10:211-18
  31. Purification and characterization of rat hepatic microsomal low molecular weight fatty acid ethyl ester synthase and its relationship to carboxylesterases. J Biochem Mol Toxicol 2001;15:165-71
  32. Increased plasma fatty acid ethyl ester levels following inhibition of oxidative metabolism of ethanol by 4-methylpyrazole treatment in human subjects. Alcohol Clin Exp Res 2006;30:1126-31
  33. Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis. Gastroenterology 1995;108: 515-22
  34. Metabolic basis of ethanolinduced cytotoxicity in recombinant HepG2 cells: Role of nonoxidative metabolism. Toxicol Appl Pharmacol 2006;216: 238-47
  35. In heavy drinkers, fatty acid ethyl esters remain elevated for up to 99 hours. Alcohol Clin Exp Res 2007;31:423-27.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.